Status: Recruiting
ONO-4538 Phase II Rollover Study (ONO-4538-98)
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Participants needed: 59
Trial details
Phase: Phase 2Age: 16+Biological sex: AllType: InterventionalSponsor: Ono Pharmaceutical Co., Ltd.Updated: Jun 3, 2025Locations: 38
Eligibility criteria
Participant who is being treated with ONO-4538 as monotherapy or in Combination... [+1]
Participant judged to be incapable of providing consent for reasons such as conc... [+1]